Literature DB >> 17028036

Cyclopamine treatment of human embryonic stem cells followed by culture in human astrocyte medium promotes differentiation into nestin- and GFAP-expressing astrocytic lineage.

Dong-Seok Lee1, Kweon Yu, Jeung-Yon Rho, Eunyoung Lee, Jee-Soo Han, Deog-Bon Koo, Yee Sook Cho, Janghwan Kim, Kyung-Kwang Lee, Yong-Mahn Han.   

Abstract

Human embryonic stem cells (hESCs) are able to differentiate into various cell types, including neuronal cells and glial cells. However, little information is available regarding astrocyte differentiation. This report describes the differentiation of hESCs into nestin- and GFAP-expressing astrocytes following treatment with cyclopamine, which is an inhibitor of Hedgehog (Hh) signaling, and culturing in human astrocyte medium (HAM). In hESCs, cyclopamine treatment suppressed the expression of Hh signaling molecules, the Hh signaling target gene, and ESC-specific markers. Clyclopamine also induced the differentiation of the cells at the edges of the hESC colonies, and these cells stained positively for the early neural marker nestin. Subsequent culturing in HAM promoted the expression of the astrocyte-specific marker GFAP, and these cells were also nestin-positive. These findings indicate that treatment with cyclopamine followed by culturing in HAM leads to the differentiation of hESCs into nestin- and GFAP-expressing astrocytic lineage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17028036     DOI: 10.1016/j.lfs.2006.08.039

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  11 in total

1.  Transcriptional expression profile of cultured human embryonic stem cells in vitro and in vivo.

Authors:  Marlen Keil; Antje Siegert; Klaus Eckert; Jörg Gerlach; Wolfram Haider; Iduna Fichtner
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-02-04       Impact factor: 2.416

Review 2.  Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells.

Authors:  Priya Srikanth; Tracy L Young-Pearse
Journal:  J Neurogenet       Date:  2014-03-17       Impact factor: 1.250

3.  Ascl1/Mash1 is a novel target of Gli2 during Gli2-induced neurogenesis in P19 EC cells.

Authors:  Anastassia Voronova; Anna Fischer; Tammy Ryan; Ashraf Al Madhoun; Ilona Sylvia Skerjanc
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

Review 4.  Stem and Progenitor Cell-Derived Astroglia Therapies for Neurological Diseases.

Authors:  Chen Chen; Albert Chan; Han Wen; Seung-Hyuk Chung; Wenbin Deng; Peng Jiang
Journal:  Trends Mol Med       Date:  2015-10-03       Impact factor: 11.951

Review 5.  Utilization of neural stem cell-derived models to study anesthesia-related toxicity and preventative approaches.

Authors:  Cheng Wang; Fang Liu; Tucker A Patterson; Merle G Paule; William Slikker
Journal:  Mol Neurobiol       Date:  2013-07-12       Impact factor: 5.590

Review 6.  Potential for pharmacological manipulation of human embryonic stem cells.

Authors:  Stuart P Atkinson; Majlinda Lako; Lyle Armstrong
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 7.  The use of pluripotent stem cell for personalized cell therapies against neurological disorders.

Authors:  Hye-Yeong Ha; Si-Hyong Jang; Ji-Won Jung
Journal:  J Biomed Biotechnol       Date:  2011-12-13

Review 8.  Human embryonic stem cell differentiation toward regional specific neural precursors.

Authors:  Slaven Erceg; Mohammad Ronaghi; Miodrag Stojković
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

9.  Advanced pre-clinical research approaches and models to studying pediatric anesthetic neurotoxicity.

Authors:  Cheng Wang
Journal:  Front Neurol       Date:  2012-10-17       Impact factor: 4.003

10.  Real-time acquisition of transendothelial electrical resistance in an all-human, in vitro, 3-dimensional, blood-brain barrier model exemplifies tight-junction integrity.

Authors:  Zaynah Maherally; Helen L Fillmore; Sim Ling Tan; Suk Fei Tan; Samah A Jassam; Friederike I Quack; Kathryn E Hatherell; Geoffrey J Pilkington
Journal:  FASEB J       Date:  2017-09-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.